Inflammatory bowel disease (IBD) is associated with immune dysregulation triggered by environmental factors, microbial dysbiosis, and genetical susceptibility. Regulatory T cells (Tregs) are critical in controlling intestinal immune homeostasis and Treg deficiencies trigger intestinal inflammation.
1,2 Interleukin (IL)-2 is a key cytokine controlling differentiation, survival, and function of Tregs. 3 In contrast to conventional T cells (Tcon), Tregs exhibit higher sensitivity to IL-2 due to constitutive expression of CD25, the high-affinity subunit of the IL-2 receptor. 3 Low-dose (LD) IL-2 has been reported to selectively expand Tregs and used as a therapeutic strategy in chronic graft-versus-host disease, hepatitis C virus-induced vasculitis, systemic lupus erythematosus, and Wiskott-Aldrich syndrome. [4] [5] [6] [7] Thus, we sought to investigate LD IL-2 as an IBD therapeutic using humanized mice.
Similar to other disease settings, [4] [5] [6] [7] LD IL-2 specifically activated peripheral blood and colonic lamina propria Tregs from patients with IBD in vitro (Supplementary Figure 1) . Figure 1A ). On day 5 following immune reconstitution, colitis was induced by rectal application of 2,4-dinitrobenzene sulfonic acid. Mice receiving 10K IL-2 had reduced weight loss and reduced histology scores compared with mice treated with PBS or 50K IL-2 ( Figure 1B and C) . Phospho-flow analysis of STAT5 confirmed that 10K IL-2 specifically activated Tregs, whereas STAT5 phosphorylation was also detected in Tcons from mice receiving 50K IL-2 ( Figure 1D ). Expansion of Tregs was observed in blood, spleen, and colon of mice treated with either dose of IL-2 ( Figure 1E ). However, reduced body weight loss upon treatment with 10K IL-2 associated with Treg expansion in the absence of significant Tcon activation suggest that a therapeutic range of LD IL-2 is critical ( Figure 1C-E) .
To evaluate the efficacy of LD IL-2 in a fully reconstituted humanized murine system, we developed NSG mice that lack murine MHCII but express human HLA-DQ8 (NSGIIDQ8 mice). Sixteenweek-old mice reconstituted with human healthy donor CD34 þ hematopoietic stem cells at birth were sensitized with 2,4,6-trinitrobenzenesulfonic acid (TNBS) and treated with 10K IL-2 daily followed by induction of colitis with TNBS rectal challenge ( Figure 2A ). In contrast to mice treated with PBS, mice receiving LD IL-2 exhibited significant improvement in histological disease activity with a trend in reduced weight loss ( Figure 2B and C). LD IL-2 was associated with significant expansion of human Tregs in the blood and spleen but not in the mesenteric lymph nodes or colon ( Figure 2D and E). Figure 3) .
Tregs have been reported to suppress pathogenic effector T cell function and autoimmunity through both contactdependent and contact-independent mechanisms. 8 þ cells based on the top 10 nodes of the SPADE analysis within the FOXP3 þ cells. Data are pooled from 3 independent experiments. *P < .05, **P < .01, ***P < .001.
inflammation (CCR4 and CCR6) ( Figure 2H ). Our data suggest that expansion and activation of memory Tregs might be critical clinical determinants.
Taken together, our study demonstrates that LD IL-2 expands Tregs and ameliorates experimental colitis in humanized mice. While these data support a rationale for LD IL-2 in IBD therapy, the safety of long-term drug administration needs further investigation to ensure continued selective activation of Tregs over Tcons. Based on these promising results, we have initiated a phase 1b/2a clinical trial investigating the safety and therapeutic efficacy of LD IL-2 in patients with moderate to severe ulcerative colitis (NCT02200445). SCOTT E. PLEVY, 6 AISLING O'HARA HALL, 6 SCOTT B. SNAPPER,
